Cipla Limited — Losartan Exporter Profile
Indian Pharmaceutical Exporter · #3 for Losartan · $9.2M export value · DGFT Verified
Cipla Limited is the #3 Indian exporter of Losartan with $9.2M in export value and 184 verified shipments. Cipla Limited holds a 3.1% market share in Losartan exports across 3 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Losartan Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Losartan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $5.1M | 138 | 89.5% |
| MADAGASCAR | $554.1K | 42 | 9.7% |
| KENYA | $47.7K | 4 | 0.8% |
Cipla Limited exports Losartan to 3 countries. The largest destination is SRI LANKA accounting for 89.5% of Cipla Limited's Losartan shipments, followed by MADAGASCAR (9.7%) and KENYA (0.8%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Losartan from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $3.4M | 92 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $1.7M | 43 |
| OPHAM | MADAGASCAR | $327.2K | 23 |
| SOMAPHAR SA | MADAGASCAR | $184.8K | 14 |
| CIPLA KENYA LTD | KENYA | $47.7K | 4 |
| OPHAM ANDRIAMAHAZO BP | MADAGASCAR | $31.8K | 2 |
| OPHAM ROUTE DIGUE ANDRANOAMBO ANDOHATAPENAKA | MADAGASCAR | $10.3K | 3 |
Cipla Limited supplies Losartan to 7 buyers globally. The largest buyer is BREATHEFREE LANKA PVT LTD (SRI LANKA), followed by BREATHEFREE LANKA PRIVATE LIMITED (SRI LANKA) and OPHAM (MADAGASCAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Losartan Export Value and How Much Does Cipla Limited Contribute?
India exported $143.4M worth of Losartan through 10,898 shipments from 506 suppliers to 141 countries, serving 1,415 buyers globally. Cipla Limited contributes $9.2M to this total, accounting for 3.1% of India's Losartan exports. Cipla Limited ships Losartan to 3 countries through 7 buyers.
What Is the Average Shipment Value for Cipla Limited's Losartan Exports?
Cipla Limited's average Losartan shipment value is $50.0K per consignment, based on 184 shipments totaling $9.2M. The largest destination is SRI LANKA (89.5% of Cipla Limited's Losartan exports).
How Does Cipla Limited Compare to Other Indian Losartan Exporters?
Cipla Limited ranks #3 among 506 Indian Losartan exporters with a 3.1% market share. The top 3 exporters are ZYDUS LIFESCIENCES LIMITED ($28.1M), MICRO LABS LIMITED ($20.5M), AUROBINDO PHARMA LTD ($13.0M). Cipla Limited processed 184 shipments to 3 destination countries.
What Losartan Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ZAART 50 TABLETS LOSARTAN POTASSIUM 50 | $653.2K | 14 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50 | $389.8K | 9 |
| ZAART 25 TAB (LOSARTAN POTASSIUM 25MG) ( | $210.0K | 5 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50M | $184.8K | 12 |
| ZAART 50 TABLETS LOSARTAN POTASSIUM 50 MG INV QTY 30240 PACK 10X10 S 3024000 NOS | $150.0K | 3 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) . (INV.QTY.30408 PACK 10 X 10S=3040800 NOS)NOS | $115.0K | 3 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) 30429 PACK 10 X 10'SNOS | $115.0K | 3 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) (INV.QTY.30357 PACK 10X10S=3035700 NOS)NOS | $114.7K | 3 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) 30324 PACK 10 X 10'SNOS | $114.6K | 3 |
| ZAART 50 TABLETS (LOSARTAN POTASSIUM 50MG) 30280 PACK 10 X 10'SNOS | $114.4K | 3 |
Cipla Limited exports 114 distinct Losartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ZAART 50 TABLETS LOSARTAN POTASSIUM 50 with 14 shipments worth $653.2K.
How Does Cipla Limited Compare to Nearest Losartan Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | ALEMBIC PHARMACEUTICALS LIMITED | $11.1M | 222 | 2 | $50.0K |
| 9 | IPCA LABORATORIES LIMITED | $9.5M | 532 | 19 | $17.8K |
| 3 | CIPLA LIMITED ★ | $9.2M | 184 | 3 | $50.0K |
| 12 | MSN LABORATORIES PRIVATE LIMITED | $7.4M | 410 | 1 | $18.2K |
| 11 | CAPLIN POINT LABORATORIES LIMITED | $7.3M | 146 | 8 | $50.0K |
Cipla Limited ranks #3 among 506 Indian Losartan exporters. Average shipment value of $50.0K compared to the market average of $283.3K. The closest competitors by value are ALEMBIC PHARMACEUTICALS LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Losartan Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,020 | 9.4% |
| NHAVA SHEVA SEA (INNSA1) | 946 | 8.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 886 | 8.1% |
| DELHI AIR CARGO ACC (INDEL4) | 702 | 6.4% |
| DELHI AIR | 672 | 6.2% |
| JNPT/ NHAVA SHEVA SEA | 549 | 5.0% |
| MUNDRA SEA | 491 | 4.5% |
| HYDERABAD ICD | 384 | 3.5% |
What Other Cardiovascular Products Does Cipla Limited Export?
Cipla Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Losartan Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Losartan, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Losartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Losartan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 184 individual customs records matching Cipla Limited exporting Losartan, covering 114 formulations to 3 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 141+ countries, 1,415+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Losartan Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Losartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Losartan Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Losartan. For current shipment-level data, contact TransData Nexus.